Longboard Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Longboard Pharmaceuticals (Nasdaq: LBPH) announced its participation in key investor conferences. The Guggenheim Healthcare Talks Neuro/Immunology Virtual Conference will take place on November 15-16, 2021, and the Evercore ISI 4th Annual HealthCONx Virtual Conference features a fireside chat on December 1, 2021, at 1:50 PM ET, with additional investor meetings from November 30 to December 2. A live webcast of the presentation will be accessible via Longboard's Investors Relations page, with replays available post-event.

SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior leadership team will participate in the following conferences:

• Guggenheim Healthcare Talks Neuro/Immunology Virtual Conference: Hosting investor meetings Monday, November 15 – Tuesday, November 16, 2021
• Evercore ISI 4th Annual HealthCONx Virtual Conference: Presenting in a fireside chat format on Wednesday, December 1, 2021, at 1:50 PM ET (Track 2) and hosting investor meetings Tuesday, November 30 – Thursday, December 2, 2021

To access a live webcast of the Evercore fireside chat presentation, please visit the “Events & Presentations” page within the Investors Relations section of Longboard’s website at https://www.longboardpharma.com/. A replay of the presentation will be available shortly after the completion of the event and archived on the website for at least 30 days.

About Longboard Pharmaceuticals
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard’s small molecule product candidates are based on more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting 5-HT2c receptor superagonist, with negligible observed impact on 5-HT2b and 5-HT2a receptor subtypes, in development for the potential treatment of seizures associated with developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, full CB2 receptor agonist, in development for the potential treatment of neurodegenerative diseases associated with neuroinflammation caused by microglial activation, and LP659, a centrally acting, S1P receptor subtypes 1 and 5 modulator, in development for the potential treatment of central nervous system neuroinflammatory diseases.

Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Longboard’s participation in the upcoming conferences, clinical and preclinical programs, ability to develop medicines, and focus. For such statements, Longboard claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Longboard’s expectations. Factors that could cause actual results to differ materially from those stated or implied by Longboard’s forward-looking statements are disclosed in Longboard’s filings with the Securities and Exchange Commission (SEC). These forward-looking statements represent Longboard’s judgment as of the time of this release. Longboard disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

FAQ

What conferences will Longboard Pharmaceuticals participate in November 2021?

Longboard Pharmaceuticals will participate in the Guggenheim Healthcare Talks Neuro/Immunology Virtual Conference on November 15-16 and the Evercore ISI 4th Annual HealthCONx Virtual Conference on December 1, 2021.

What is the schedule for Longboard Pharmaceuticals during the Evercore ISI HealthCONx Conference?

During the Evercore ISI conference, Longboard Pharmaceuticals will present a fireside chat on December 1, 2021, at 1:50 PM ET, and host investor meetings from November 30 to December 2, 2021.

How can I watch Longboard Pharmaceuticals' presentation at the Evercore ISI conference?

You can access a live webcast of Longboard Pharmaceuticals' fireside chat presentation on the Investors Relations section of their website.

What is the focus of Longboard Pharmaceuticals?

Longboard Pharmaceuticals is focused on developing transformative medicines for neurological diseases, specifically targeting G protein-coupled receptors.

What are the product candidates being developed by Longboard Pharmaceuticals?

Longboard Pharmaceuticals is evaluating LP352 for seizures, LP143 for neurodegenerative diseases, and LP659 for central nervous system neuroinflammatory diseases.